Swiss drug maker Roche has brought in U.S. PR support to bolster its $5.7B hostile pursuit of gene sequencing company Illumina, which rejected the overture this week as “grossly inadequate.”

Read the full story (sub req'd) | Subscribe to O'Dwyer's